Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

BAT-90 A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’

Coordinator
Betaglue Therapeutics SpA, Italy
Runs
1 April 2024 to 31 December 2025
Status
Running
EU funding
€2.5m
Total cost
€7.1m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101164662

What the project is doing

In the project's own words, from its summary on CORDIS.

BetaGlue is developing an innovative ""radiotherapy from within"", personalized and cost-effective anti-tumoural platform technology called BAT-90. BAT-90 maximises the therapeutic index of loco-regional treatment by eliminating off-target radiation dose in a simple and easy to use product. The product aims to provide a radiotherapeutic treatment option for a range of solid tumour types including: unresectable hepatocellular carcinoma (HCC) and locally advanced and borderline resectable pancreatic cancer (PDAC) patients, where in the first-line setting, there exists a major unmet clinical need.

Through the percutaneous administration of BAT-90 under radiological guidance (usually ultrasound) BAT-90 overcomes the accessibility and off-target side effect limitations of external beam radiotherapy, forms of brachytherapy, proton beam radiotherapy trans-arterial radio-embolisation and microwave ablation. BAT-90 has already demonstrated safety and preliminary effectiveness in first-in-human clinical studies.""

Topics

Who is involved

OrganisationCityCountryRole
Betaglue Therapeutics SpAMilanoItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI